主要文件

查看所有文档

C2174000

西拉普利

Name: 西拉普利
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

别名:

Cilazapril monohydrate

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₂₂H₃₁N₃O₅ · H₂O

化学文摘社编号:

92077-78-6

分子量:

435.51

UNSPSC Code:

41116107

MDL number:

MFCD01692810

NACRES:

NA.24

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

grade

pharmaceutical primary standard

API family

cilazapril

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

N21N(CCC[C@H]2C(=O)O)CCC[C@@H](C1=O)N[C@@H](CCc3ccccc3)C(=O)OCC.O

InChI

1S/C22H31N3O5.H2O/c1-2-30-22(29)18(13-12-16-8-4-3-5-9-16)23-17-10-6-14-24-15-7-11-19(21(27)28)25(24)20(17)26;/h3-5,8-9,17-19,23H,2,6-7,10-15H2,1H3,(H,27,28);1H2/t17-,18-,19-;/m0./s1

InChI key

JQRZBPFGBRIWSN-YOTVLOEGSA-N

说明

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Cilazapril EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Short-term effects of cilazapril and atenolol on P-wave dispersion in patients with hypertension.

Mustafa Tuncer et al.

Advances in therapy, 25(2), 99-105 (2008-02-26)

P-wave dispersion (PWD) has been shown to be a non-invasive electrocardiographic predictor for development of atrial fibrillation (AF). Thus, it may be possible to decrease AF risk through improvement in PWD. Our objective was to compare the effects of cilazapril

Blood pressure and cardiorenal responses to antihypertensive therapy in obese women.

Eduardo Cantoni Rosa et al.

Arquivos brasileiros de endocrinologia e metabologia, 52(1), 65-75 (2008-03-18)

Blood pressure (BP) and target organ responses to antihypertensive drugs are not well established in hypertensive obese patients. This study is aimed at evaluating the effects of obesity and adiposity distribution patterns on these responses. 49 hypertensive obese women were

Reversible posterior encephalopathy syndrome in systemic lupus erythematosus and lupus nephritis.

Yan-Xing Zhang et al.

Internal medicine (Tokyo, Japan), 47(9), 867-875 (2008-05-03)

Reversible posterior encephalopathy syndrome (RPES) is a clinical entity characterized with headache, nausea, vomiting, seizures, consciousness disturbance, and frequently visual disorders associated with neuroradiological findings, predominantly white matter abnormalities of the parieto-occipital lobes. The central nervous system manifestations of systemic

查看所有相关文献

全球贸易项目编号

货号	GTIN
C2174000	04061833475249